NSCLC
mCRPC
CRC
PDAC
UPPER GI
Advanced Malignancies
Healthy Participants
Domvanalimab
(DOM)
FC-SILENT ANTI-TIGIT ANTIBODY
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
NSCLC
Quemliclustat
CD73 Inhibitor Small Molecule
Etrumadenant
(ETRUMA)
Dual A2a/A2b Adenosine Receptor Antagonist Small Molecule
NSCLC
NSCLC
CRPC
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab;
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
(c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.
*+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.
Etrumadenant: Dual A2aR/A2bR Antagonist Small Molecule
Quemliclustat: CD73 Inhibitor Small Molecule
Domvanalimab: TIGIT mAb
Zimberelimab: PD-1 mAb
These molecules and their uses are investigational, have not been proven to be safe, and have not been approved by the U.S. Food and Drug Administration.
ABBREVIATIONS:
atezo: atezolizumab; bev: bevacizumab; carbo/pem: carboplatin/pemetrexed; doce: docetaxel; dom: domvanalimab; enza: enzalutamide; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; nivo: nivolumab; pembro: pembrolizumab; PLD: pegylated liposomal doxorubicin; quemli: quemliclustat; rego: regorafenib; SOC: standard of care; zim: zimberelimab
CRC=colorectal cancer; CRPC=castrate-resistant prostate cancer; GI=gastrointestinal; NSCLC=non-small cell lung cancer; PDAC=pancreatic ductal adenocarcinoma; RCC=renal cell carcinoma
PARTNERSHIPS & COLLABORATIONS:
(a) In May 2020, Arcus and Gilead announced a 10-year partnership to co-develop and co-commercialize next-generation cancer immunotherapies. The parties will co-develop Gilead-optioned programs globally, and will co-commercialize in the U.S., with Gilead commercializing outside of the U.S., subject to the rights of Arcus’s existing partners for such programs.
(b) In September 2017, Arcus and Taiho announced an option and license agreement. Taiho has an option to Arcus’s programs arising during the 5-year term for Japan and certain other Asian territories (excluding China).
(c) Arcus and AstraZeneca are collaborating on PACIFIC-8, a registrational Phase 3 clinical trial, to evaluate domvanalimab plus durvalumab (Imfinzi®) in unresectable Stage 3 NSCLC with curative intent, where durvalumab is standard of care.